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Abstract 
Introduction: Azacitidine is a therapeutic alternative to low-dose cytarabine in patients with 
acute myeloid leukemia (AML) unfit for intensive chemotherapy.  
Patients and Methods: We retrospectively analyzed all AML patients treated with azacitidine 
at the University Hospital Zurich and the Kantonsspital Munsterlingen between January 2005 
and December 2011. Primary end-point was overall survival.  
Results: Thirty-eight patients were included in the analysis. Twenty-one (55%) patients had 
newly diagnosed AML, 14 (37%) relapsed AML, and 3 (8%) underwent bridging therapy prior 
to allogeneic stem cell transplantation (SCT). Age at diagnosis was 72 years in the newly 
diagnosed and 58 in the relapsed cohort, 19 (50%) patients were female, 20 (53%) patients 
were transfusion dependent, and the bone marrow blast count was 43% (IQR 26-80). Most 
patients (58%) had poor or very-poor risk AML. Patients received a median of 7 (3-13) 
therapy cycles. The median overall-survival in the newly diagnosed and the previously 
treated patient groups were 308 (175-580) and 346 (293-628) days, respectively (p=0.94). 
Median OS in the three patients treated prior to allogeneic SCT has not been reached. 60 day 
mortality was 7.9% with no difference in the two groups. Ongoing or increasing transfusion 
dependency was associated with adverse outcome (HR 3.09; 95% CI 1.29-7.37; p=0.011).  
Conclusions: Treatment with azacitidine led to a median overall survival of 10 months in 
both, a previously untreated and a previously treated frail AML patient cohort. A positive 
effect in transfusion dependency was observed in 29% of these patients and was associated 
with better survival. 
 
MicroAbstract 
Azacitidine is a treatment option for patients with acute myeloid leukemia (AML) who 
cannot tolerate intensive chemotherapy. It is still unknown which patients will benefit most 
from azacitidine treatment. Therefore, we conducted a retrospective comparative study on 
forty patients with newly diagnosed and relapsed AML. We found no significant difference in 
overall survival time (10 months) between these two patient groups. Prior treatment does 
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not predict poor outcome. Achievement of transfusion independency was associated with 
longer survival. 
 
Clinical Practice Points 
• Clinical response of non- intensive chemotherapy in patient with AML is unsatisfactory 
• Some patients with AML do respond to treatment with hypomethylating agents such as 
azacitidine and decitabine. However, response to treatment cannot yet be predicted. 
• A head to head efficacy analysis of azacitidine in previously treated, relapsed patients 
and newly diagnosed patients is lacking. 
• Our data shows that treatment with azacitidine leads to a median overall survival of 10 
months both in pretreated patients as well as newly diagnosed patients. 
• All patients with azacitidine not undergoing allogeneic stem cell transplantation 
eventually died. 
• Achievement of transfusion independence is associated with better outcome 
• Treatment with azacitidine is associated with a relatively low early mortality rate (<10%). 
•  The need for hospitalization was 15 days in the newly diagnosed and 32 in the 
previously treated patient group, respectively (p=0.349). 
• Pretreatment did not lead to an inferior outcome in our patient cohort. Better predictors 
for a response to hypomethylating agents in AML are needed. 
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Introduction 
Acute myeloid leukemia (AML) affects 2-4/100000 persons annually resulting in 
approximately 160 to 320 new diagnoses in Switzerland per year.1 AML has an increasing 
incidence by age.2 A substantial fraction of younger AML patients can be cured with 
intensive chemotherapy, and indeed,  data from the Swedish Acute Leukemia Registry have 
shown that outcome is also improved in elderly patients undergoing intensive chemotherapy 
compared to other treatment options; nevertheless the majority of patients will not undergo 
intensive chemotherapy for various reasons, particularly due to higher therapy associated 
morbidity and mortality as well as overall decreased response rates.3-5 In patients not 
treated with intensive chemotherapy, low-dose cytarabine is superior to best supportive 
care and has long been considered the standard of care for these patients.6 However, in 
recent years novel drugs such as the epigenetic modifiers azacitidine and decitabine have 
emerged as treatment options for patients with hematologic malignancies. Azacitidine and 
decitabine are nucleoside analogues of cytidine. Their antineoplastic effect seems to be 
related to DNA hypomethylation.7 Azacitidine has been shown to lead to a statistically 
significant increase in life-expectancy in patients with high-risk myelodysplastic syndromes 
(MDS) as well as in patients with AML with myelodysplasia-related changes and a low blast 
count of 20-30%. 8,9 As a consequence, these results raised interest in using azacitidine and 
decitabine in AML patients with bone marrow blast counts of 30% and more. In our 
institutions we started to study the off-label use of azacitidine in selected AML patients unfit 
for intensive chemotherapy in 2005.  
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Patients and Methods 
Patients and clinical data 
Patients 18 years of age or older with a confirmed diagnosis of AML according to the WHO 
2008 criteria and a blast count of ≥20% were eligible if they received at least one cycle of 
azacitidine. Patients received azacitidine either because they chose not to undergo intensive 
therapy, or because they were considered unfit for intensive chemotherapy by their treating 
physicians based on their age, performance status, comorbidities or unlikely to achieve 
lasting remissions upon intensive chemotherapy due to disease biology as determined by 
cytogenetics.10 Azacitidine was considered the treatment of choice in patients with early 
relapse after intensive chemotherapy (< 6 months), and no available allogeneic stem cell 
donor. Both newly diagnosed as well as pretreated patients were included. However, 
patients participating in the SAKK 30/07 trial were excluded from the analysis, and have 
been reported elsewhere.11 Patient inclusion lasted from January 1st, 2005 to December 31st, 
2011. End of follow-up was June 30th, 2014. Clinical information was extracted from patient’s 
charts. The retrospective study was approved by the local ethical committees of the Kanton 
Zurich and Kanton Thurgau, Switzerland (KEK-ZH-Nr.2012-0402). 
 
Treatment regimes 
Treatment with azacitidine could be administered subcutaneously at a dose of 100mg/m2 for 
five consecutive days or at a dose of 75mg/m2 for 7 consecutive days of a 28 day cycle. Most 
outpatients were treated according to the 5-days schedule. No standard anti-infectious 
prophylaxis was employed. The choice of supportive care, including the transfusion policy 
was left to the treating physicians’ discretion. 
 
End points 
Primary end-point was overall survival. Secondary end-points were 60 day mortality, 
hospitalisation days, transfusion dependency, response to azacitidine, median number of 
treatment cycles, and azacitidine side effects.12 
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Statistical Analysis 
We calculated descriptive statistics. Data were reported as proportions, and medians with 
interquartile ranges (IQR). Data were presented separately for the subgroup of patients with 
newly diagnosed AML, previously treated AML and Patients who underwent bridging 
therapy prior to allogeneic stem cell transplantation. Patient characteristics among groups 
were compared by non-parametric tests as appropriate. Survival after initiation of 
azacitidine treatment was estimated by the Kaplan-Meier method and log-rank test was 
used to compare survival curves. Univariate cox regression analysis was applied to 
investigate potential associations between survival and patient characteristics such as 
transfusion dependency, performance status (ALMA score) and AML risk score 
 
Results 
Patient characteristics 
Forty patients were screened, two had to be excluded due to incomplete follow-up data, and 
thirty-eight were included in the analysis. Twenty-one (55%) patients had newly diagnosed 
AML, 14 (37%) AML relapse, and 3 (8%) underwent bridging therapy prior to allogeneic stem 
cell transplantation. The median age at diagnosis was 67 years. Newly diagnosed patients 
were significantly older than patients with relapsed AML (median 72.2 years (IQR 67.6 – 
77.2) vs. 58.1 years (IQR 51.9-64.9); p=0.001). Nineteen (50%) patients were female, 20 
(53%) patients were transfusion dependent and the median bone marrow blast count at 
diagnosis was 43% (interquartile range 26-80). More than half of the patients (58%) had 
poor or very-poor risk AML according to the HOVON/SAKK 102 risk stratification. The 
European ALMA score was 2 (IQR 1-3) for all treatment groups. 
Patients were then further stratified in a newly diagnosed group, a previously treated group 
and patients with bridging therapy prior to allogeneic stem cell transplantation (Table 1). The 
main reasons for azacitidine treatment in the newly diagnosed patients were age (median 
age 78.3 years, IQR 76.7-79.3) (38%), ECOG ≥2 and/or significant co-morbidities (29%), 
followed by unfavorable caryotype (14%) and patient choice (14%). Time to azacitidine 
7 
Gemünden et al. Azacitidine in AML 27.08.2015 
treatment was significantly shorter in the newly-diagnosed group as they did not undergo 
prior AML treatment (median 10.5 days (IQR 7-31) vs. 247 days (IQR 142-417); p=0.001). 
Seventy-one percent in the newly diagnosed and 30% in the relapsed AML patients needed 
blood transfusions during the 30 days prior to azacitidine treatment (p=0.036). The bone 
marrow blast count was 40% in the newly diagnosed, and 32.5% in the relapsed patients 
(p=0.11). The median number of azacitidine cycles was 7 and 7.5, respectively (Table 2) 
 
Survival 
The median overall survival (OS) after initiation of azacitidine therapy did not differ 
significantly between the newly diagnosed and the previously treated patient group with 
308 (175-580), and 346 (293-628), respectively (p=0.94). Median OS in the three patients 
with bridging therapy prior to allogeneic stem cell transplantation was not reached.  
As of June 30th 2014, two and a half years after inclusion of the last patient, only two 
patients were still alive.  Patient one with good-risk AML (AML with mutated NPM1A) went 
into complete remission after intensive induction chemotherapy but suffered from severe 
complications. He then had one cycle of azacitidine bridging prior to allogeneic 
hematopoietic stem-cell transplantation (HSCT). Patient two had an early molecular relapse 
of a good-risk AML (AML with mutated NPM1A) after induction and consolidation therapy. 
He was given one azacitidine bridging cycle prior to allogeneic HSCT.  
 
Transfusion dependency and response to therapy 
A decrease in the transfusion dependency was seen in 43% of the patients with newly 
diagnosed AML and 12% of the patients in the pre-treated AML group (Table 2). Follow-up 
bone marrow biopsies were performed in nine out of 21 patients (43%) with newly 
diagnosed AML, ten out of 14 patients (71%) with previously treated AML, and all three 
patients with a bridging therapy. In the newly diagnosed and the previously treated patient 
group three (14%), and two (14%) patients showed complete remission, three (14%), and 
two (14%) partial remission, three (14%), and four (29%) stable disease, respectively. Two 
(14%) patients in the previously treated group had primary disease progression. All three 
patients with a bridging therapy had ongoing complete remission.   
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Sixty day mortality and hospitalisation days 
Three patients (7.9%) died during the first 60 days of azacitidine treatment. Total 
hospitalization duration including the days from diagnosis to treatment start was 15 (IQR 6-
30), and 32 (IQR 9-49) days in the previously untreated and the pretreated patients group, 
respectively. This accounts for 4.8% and 9.2% of the median overall survival time in these 
patient groups.  
 
Side effects 
One patient died of pneumonitis, and even though several reasons such as heart failure, 
infectious complications and a preexisting lung disease might have contributed to this fatal 
event, a toxic side effect of azacitidine cannot be ruled out completely. No other severe 
unexpected side effects were noted. Due to the lack of a comparator, myelotoxicity could 
not be evaluated. 
 
Survival risk factors 
On univariate analysis ongoing or increasing transfusions dependency (Hazard ratio (HR) 
3.09, 95% confidence interval (CI) 1.29-7.37, p = 0.011), as well as an ECOG of 3 or higher 
(n=3) when compared to ECOG ≤1 (n=18) (HR 4.5, 95% CI 1.32-15.18, p=0.016) were 
significantly associated with increased mortality.  European ALMA score (HR 1.5, 95% CI 
0.94-2.42, p=0.088), as well as European ALMA risk groups (p=0.093) were not predictive of 
overall survival, neither were the SAKK/HOVON defined poor and very poor-risk AML 
categories (HR 1.5, 95% CI 0.69-3.15, p=0.319), the leukocyte count at diagnosis (HR 1.0, 95% 
CI 0.99-1.0, p=0.208), the age at diagnosis (HR 0.99, 95% CI 0.96-1.04, p=0.932) and the blast 
count at the start of azacitidine treatment (HR 1.01, 95% CI 1.0-1.02, p=0.069). 
 
Discussion and Conclusion 
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We here report real-world long-term follow-up data from patients with acute myeloid 
leukemia (AML) treated with azacitidine. Median overall survival in both, the previously 
untreated as well as the previously treated patient group was 10 months. The patients had 
to be hospitalized during 4.8% and 9.2% of the median overall survival time, which is less 
than reported elsewhere.13 Early mortality within the first sixty days was low (7.9%). 
However, treatment with azacitidine is not curative. All patients who did not undergo 
subsequent allogeneic hematopoietic stem cell transplantation eventually died. 
. We believe, that the lack of a difference in overall survival between the previously treated 
and the previously untreated patient group can mainly be explained by a counterbalance of 
risk factors. The patients with the supposedly more favorable newly diagnosed  AML were 
significantly older, while relapsed patients had previously been exposed to intensive 
chemotherapy and were more likely to be transfusion dependent. The median overall 
survival time in both our patient groups is comparable to what has been recently reported. 
14-18 Interestingly, decitabine has shown comparable results in AML patients, but a head-to-
head comparison is lacking. 19 Hence, both decitabine and azacitidine seem to be effective 
and associated with low toxicity, but are only slightly superior to low-dose cytarabine, if 
superior at all.18,19 
A key question is which AML patients should receive and will profit most from 
hypomethylating agents (HMA)? In our patient cohort, achieving transfusion independency 
was clearly associated with better overall survival. Hence, we do know, that hematologic 
responders do better than non- responders.20 But earlier predictors of an HMA treatment 
response are warranted. As for now, no large randomized trials included comprehensive 
biomarker analysis to better understand potential markers predictive of treatment 
response.18 Meanwhile, in an attempt to use clinical information to predict treatment 
outcome, the so-called European ALMA score has been proposed for patients with AML.14 It 
identifies three patient subsets with different overall survival and HMA treatment responses 
based on the initial white blood cell count, ECOG and cytogenetic abnormalities. However, 
we were not able to reproduce these data in our patient cohort which might be explained by 
differences in sample size as well as patient characteristics, as we included pretreated and 
not only newly diagnosed patients in our analysis. Patients with an ECOG of 3 or higher 
showed increased mortality, but the number of patients in our study was small (n=3). 
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Our retrospective study does have limitations as we only report the results of a relatively 
small and heterogeneous patient population, who has been judged to be unfit for intensive 
chemotherapy by their treating physicians and not by a clearly defined study protocol. 
Nevertheless,  our real-world data might add information and insights to better counsel 
patients on what can be expected from a treatment with azacitidine.   
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Table 1: Baseline characteristics of patients 
 newly diagnosed 
AML 
n= 21 
previously 
treated AML 
n = 14 
Bridging to 
allogeneic SCT 
n=3 
 
age§ 72.2 (67.6 – 
77.2) 
58.1 (51.9-64.9) 59.6 (57.8-66.2) p=0.001 
sex (%) 
- male 
- female 
 
10 (47) 
11 (53) 
 
7 (50) 
7 (50) 
 
2 (67) 
1 (33) 
p=1.0 
ECOG 1 (1-2) 1.5 (1-2) 2 (1-3) p=0.676 
diagnosis# (%) 
- AML NOS 
- AML with mutated NPM1A 
- AML with myelodysplasia-related 
changes 
- therapy-related AML 
- myeloid sarcoma 
 
7 (33) 
1 (5) 
7 (33) 
 
4 (19) 
2 (10) 
 
3 (21) 
3 (21) 
7 (50) 
 
1 (7) 
0 
 
1 (33) 
2 (67) 
0 
 
0 
0 
 
p=0.177 
AML risk at diagnosis& (%) 
- good 
- intermediate 
- poor 
- very poor 
- not known 
 
1 (5) 
7 (33) 
8 (38) 
4 (19) 
1 (5) 
 
2 (14) 
1 (7) 
8 (57) 
2 (14) 
1 (7) 
 
2 (67) 
1 (33) 
0 
0 
0 
p=0.111 
bone marrow blast count§ 
- diagnosis 
- start of azacitidine treatment 
 
40 (28-83) 
40 (28-83) 
 
42.5 (25-68.8) 
32.5 (8.8-56.3) 
 
30 (5-80) 
5 (5-5) 
 
p=0.722 
p=0.012 
leukocyte count§ 
- diagnosis 
 
7.1 (1.7-19.8) 
 
3 (2-36.7) 
 
3.2 (2.4-20.7) 
 
p=0.982 
transfusion dependence+ 
- platelet 
- red blood cells 
- platelets and red blood cells 
- none 
 
4 (19) 
9 (43) 
2 (9) 
6 (29) 
 
0 
3 (18) 
2 (12) 
9 (70) 
 
0 
0 
0 
3 (100) 
 
p=0.127 
prior therapy 
- induction chemotherapy 
- allogeneic stem cell transplantation 
 
na 
na 
 
13 (94) 
1 (6) 
 
3 (100) 
0 
 
European ALMA Score (IQR)14  2 (1-3) 2 (1-3) 2 (1-3) p=0.935 
Days to azacitidine treatment from 
primary diagnosis§ 
10.5 (7-31) 247 (142-417) 84 (65-477) p=0.001 
§ median (IQR), # according the WHO 2008 classification, & according the SAKK102/HOVON study 
 protocol, + one month prior to azacitidine treatment 
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Table 2: Outcome analysis 
 Newly diagnosed 
AML 
(n = 21) 
Previously 
treated AML 
(n=14) 
Bridging to 
allogeneic SCT 
(n=3) 
 
therapy cycles§ 7 (3-13) 7.5 (5.8-12.8) 1 (1-3) p=0.037 
overall survival (days) §+ 308 (175-580) 346 (293-628) min. 787; max. 
1210 (=end of 
follow up) 
p=0.022 
60 day mortality, N (%) 2 (9.5) 1 (7.1) 0 (0) p=1.0 
hospitalization (days) § 15 (6-30) 32 (9-49) 21 (0-61) p=0.349 
transfusion dependency (%) 
- stable 
- decrease 
- increase 
- not known 
 
4 (19) 
9 (43) 
7 (33) 
1 (5) 
 
 
3 (22) 
2 (14) 
9 (64) 
0 
 
 
3 (100) 
0 
0 
0 
p=0.030 
§ median (IQR), + following day one of the azacitidine treatment  
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Figure 1: Overall survival after initiation of azacitidine treatment. 
The median overall survival after azacitidine initiation was 308 days (IQR 175-580; min. 22, 
max. 1031) days in the newly diagnosed, and 346 (IQR 293-628; min. 46 max. 832) days in 
the previously treated patient group (p=0.94). One patient in the previously treated group, 
who had bridging therapy prior to allogeneic stem cell transplantation died after 787 days, 
the other two patients with bridging therapy prior to allogeneic stem cell transplantation 
were still alive at end of follow up (1210 days). 
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